Research progress on combined treatment of radiotherapy and anti-CTLA-4 antibody / 中华放射肿瘤学杂志
Chinese Journal of Radiation Oncology
; (6): 975-978, 2021.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-910501
Responsible library:
WPRO
ABSTRACT
Radiotherapy (RT) is one of the three prevailing therapeutics for tumors. With rapid development of immunotherapy (IM), the combination of IM and RT has gainned increasingly widespread attention. Cytotoxic T lymphocyte associated protein-4(CTLA-4) inhibitor is an important checkpoint target in immune activation and regulation, which exerts significant anti-tumor effects in melanoma and non-small cell lung cancer, etc. Accordingly, the combination of RT and anti-CTLA-4 antibody has become a hot spot. This article reviews research progress on pre-clinical and clinical evidences of RT combined with anti-CTLA-4 antibody, which provides evidence for further exploration in this field.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Radiation Oncology
Year:
2021
Document type:
Article